{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:15:24Z","timestamp":1792178124909,"version":"4.4.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40261-023-01251-0","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T05:03:24Z","timestamp":1678251804000},"page":"227-239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?"],"prefix":"10.1007","volume":"43","author":[{"given":"Aurora","family":"Gonzalez-Fierro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Romo-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Ch\u00e1vez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Dominguez-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2956-645X","authenticated-orcid":false,"given":"Alfonso","family":"Duenas-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"1251_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021. https:\/\/doi.org\/10.1002\/ijc.33588. (Epub 5 Apr 2021).","journal-title":"Int J Cancer"},{"issue":"16","key":"1251_CR2","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1002\/cncr.33586","volume":"127","author":"T Fadelu","year":"2021","unstructured":"Fadelu T, Rebbeck TR. The rising burden of cancer in low- and middle-human development index countries. Cancer. 2021;127(16):2864\u20136. https:\/\/doi.org\/10.1002\/cncr.33586.","journal-title":"Cancer"},{"issue":"24","key":"1251_CR3","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1002\/cncr.34479","volume":"128","author":"KA Cronin","year":"2022","unstructured":"Cronin KA, Scott S, Firth AU, Sung H, Henley SJ, Sherman RL, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics. Cancer. 2022;128(24):4251\u201384. https:\/\/doi.org\/10.1002\/cncr.34479.","journal-title":"Cancer"},{"issue":"3","key":"1251_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","volume":"8","author":"JM Kocarnik","year":"2022","unstructured":"Global Burden of Disease 2019 Cancer Collaboration, Kocarnik JM, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019. JAMA Oncol. 2022;8(3):420. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6987.","journal-title":"JAMA Oncol"},{"issue":"9499","key":"1251_CR5","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/S0140-6736(05)67725-2","volume":"366","author":"G Danaei","year":"2005","unstructured":"Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005;366(9499):1784\u201393. https:\/\/doi.org\/10.1016\/S0140-6736(05)67725-2.","journal-title":"Lancet"},{"issue":"1","key":"1251_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1749-6632.1997.tb48599.x","volume":"833","author":"MB Sporn","year":"1997","unstructured":"Sporn MB. The war on cancer: a review. Ann N Y Acad Sci. 1997;833(1):137\u201346. https:\/\/doi.org\/10.1111\/j.1749-6632.1997.tb48599.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"1251_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3322\/caac.21557","volume":"69","author":"RA Smith","year":"2019","unstructured":"Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019;69(3):184\u2013210. https:\/\/doi.org\/10.3322\/caac.21557.","journal-title":"CA Cancer J Clin"},{"issue":"35","key":"1251_CR8","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/JCO.22.00535","volume":"40","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Michaeli T. Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new cancer drugs, 2003\u20132021. J Clin Oncol. 2022;40(35):4095\u2013106. https:\/\/doi.org\/10.1200\/JCO.22.00535.","journal-title":"J Clin Oncol"},{"key":"1251_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000285","author":"GW Prager","year":"2018","unstructured":"Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, et al. Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO Open. 2018. https:\/\/doi.org\/10.1136\/esmoopen-2017-000285.","journal-title":"ESMO Open."},{"issue":"6","key":"1251_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrclinonc.2013.55","volume":"10","author":"G de Lima Lopes","year":"2013","unstructured":"de Lima Lopes G, de Souza JA, Barrios C. Access to cancer medications in low- and middle-income countries. Nat Rev Clin Oncol. 2013;10(6):314\u201322. https:\/\/doi.org\/10.1038\/nrclinonc.2013.55.","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"1251_CR11","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S1470-2045(15)00218-1","volume":"16","author":"K Strasser-Weippl","year":"2015","unstructured":"Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, Bychkovsky BL, Debiasi M, Liedke PER, et al. Progress and remaining challenges for cancer control in Latin America and the Caribbean. Lancet Oncol. 2015;16(14):1405\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(15)00218-1.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1251_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/14737167.2018.1444479","volume":"18","author":"G Haitsma","year":"2018","unstructured":"Haitsma G, Patel H, Gurumurthy P, Postma MJ. Access to anti-cancer drugs in India: Is there a need to revise reimbursement policies? Expert Rev Pharmacoecon Outcomes Res. 2018;18(3):289\u201396. https:\/\/doi.org\/10.1080\/14737167.2018.1444479.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"1251_CR13","doi-asserted-by":"publisher","first-page":"div370","DOI":"10.1093\/jnci\/djv370","volume":"108","author":"SY Zafar","year":"2016","unstructured":"Zafar SY. Financial toxicity of cancer care: it\u2019s time to intervene. J Natl Cancer Inst. 2016;108(5):div370. https:\/\/doi.org\/10.1093\/jnci\/djv370.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1251_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cncr.30369","volume":"123","author":"JA de Souza","year":"2017","unstructured":"de Souza JA, Yap BJ, Wroblewski K, Blinder V, Ara\u00fajo FS, Hlubocky FJ, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for Financial Toxicity (COST). Cancer. 2017;123(3):476\u201384. https:\/\/doi.org\/10.1002\/cncr.30369.","journal-title":"Cancer"},{"issue":"9","key":"1251_CR15","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","volume":"34","author":"SD Ramsey","year":"2016","unstructured":"Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34(9):980\u20136. https:\/\/doi.org\/10.1200\/JCO.2015.64.6620.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1251_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","volume":"14","author":"V Prasad","year":"2017","unstructured":"Prasad V, De Jes\u00fas K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14(6):381\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2017.31.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1251_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673\u201383. https:\/\/doi.org\/10.1038\/nrd1468.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1251_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.drudis.2018.01.018","volume":"23","author":"NC Baker","year":"2018","unstructured":"Baker NC, Ekins S, Williams AJ, Tropsha A. A bibliometric review of drug repurposing. Drug Discov Today. 2018;23(3):661\u201372. https:\/\/doi.org\/10.1016\/j.drudis.2018.01.018.","journal-title":"Drug Discov Today"},{"key":"1251_CR19","unstructured":"Coghlan A. Cheap, \u2018safe\u2019 drug kills most cancers. https:\/\/www.newscientist.com\/article\/dn10971-cheap-safe-drug-kills-most-cancers\/. Accessed 11 Dec 2022."},{"key":"1251_CR20","unstructured":"A low-cost drug from the 1960s could help treat colon cancer. https:\/\/scitechdaily.com\/a-low-cost-drug-from-the-1960s-could-help-treat-colon-cancer\/. Accessed 11 Dec 2022."},{"key":"1251_CR21","unstructured":"Could cheap drugs (up to a century old) be the new way to tackle cancer? That\u2019s the intriguing question raised by patients who swear they work\u2014but profit hungry big pharma is ignoring them \u2026 https:\/\/www.dailymail.co.uk\/health\/article-7298799\/Could-cheap-drugs-century-old-new-way-tackle-cancer.html. Accessed 11 Dec 2022."},{"key":"1251_CR22","unstructured":"Cheap drug for common cold can stop spread of cancer. https:\/\/zeenews.india.com\/health\/cheap-drug-for-common-cold-can-stop-spread-of-cancer-1941384. Accessed 11 Dec 2022."},{"key":"1251_CR23","unstructured":"Could these cheap drugs hold a cure for cancer. https:\/\/www.telegraph.co.uk\/health-fitness\/body\/crowdfunding-cure-cancer\/. Accessed 11 Dec 2022."},{"issue":"1","key":"1251_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/drrr.2014.0002","volume":"1","author":"HAM Mucke","year":"2015","unstructured":"Mucke HAM. A new journal for the drug repurposing community. Drug Repurp Rescue Repos. 2015;1(1):3\u20134. https:\/\/doi.org\/10.1089\/drrr.2014.0002.","journal-title":"Drug Repurp Rescue Repos"},{"issue":"5 Suppl 68","key":"1251_CR25","first-page":"S-5","volume":"29","author":"TG Benedek","year":"2011","unstructured":"Benedek TG. History of the development of corticosteroid therapy. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S-5-S\u221212.","journal-title":"Clin Exp Rheumatol"},{"key":"1251_CR26","volume-title":"Holland-Frei cancer medicine","author":"LI McKay","year":"2003","unstructured":"McKay LI, Cidlowski JA, et al. Corticosteroids in the treatment of neoplasms. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, et al., editors. Holland-Frei cancer medicine. 6th ed. Hamilton: BC Decker; 2003.","edition":"6"},{"key":"1251_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bpobgyn.2020.07.012","volume":"69","author":"GC Di Renzo","year":"2020","unstructured":"Di Renzo GC, Tosto V, Tsibizova V. Progesterone: history, facts, and artifacts. Best Pract Res Clin Obstet Gynaecol. 2020;69:2\u201312. https:\/\/doi.org\/10.1016\/j.bpobgyn.2020.07.012.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1251_CR28","unstructured":"Depo-Provera. https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=666. Accessed 12 Dec 2022"},{"issue":"1","key":"1251_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0305-7372(89)90004-2","volume":"16","author":"L Schacter","year":"1989","unstructured":"Schacter L, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L. Megestrol acetate: clinical experience. Cancer Treat Rev. 1989;16(1):49\u201363. https:\/\/doi.org\/10.1016\/0305-7372(89)90004-2.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1251_CR30","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/ijms21051682","volume":"21","author":"M Gomes-Porras","year":"2020","unstructured":"Gomes-Porras M, C\u00e1rdenas-Salas J, \u00c1lvarez-Escol\u00e1 C. Somatostatin analogs in clinical practice: a review. Int J Mol Sci. 2020;21(5):1682. https:\/\/doi.org\/10.3390\/ijms21051682.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1251_CR31","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.3390\/ijms20123049","volume":"20","author":"AK Stueven","year":"2019","unstructured":"Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci. 2019;20(12):3049. https:\/\/doi.org\/10.3390\/ijms20123049.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1251_CR32","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1021\/jo01016a043","volume":"30","author":"TC Myers","year":"1965","unstructured":"Myers TC, Nakamura K, Danielzadeh AB. Phosphonic acid analogs of nucleoside phosphates. III. The synthesis of adenosine-5\u02b9-methylenediphosphonate, a phosphonic acid analog of adenosine-5\u02b9 -diphosphate 1,2. J Org Chem. 1965;30(5):1517\u201320. https:\/\/doi.org\/10.1021\/jo01016a043.","journal-title":"J Org Chem"},{"issue":"3","key":"1251_CR33","first-page":"S345","volume":"26","author":"H Fleisch","year":"1968","unstructured":"Fleisch H, Russell RG, Bisaz S, M\u00fchlbauer R. Influence of diphosphonates on the deposition and dissolution ofccalcium phosphate in vitro and in vivo. Helv Physiol Pharmacol Acta. 1968;26(3):S345\u20136.","journal-title":"Helv Physiol Pharmacol Acta."},{"issue":"7625","key":"1251_CR34","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0140-6736(69)92293-4","volume":"294","author":"CAL Bassett","year":"1969","unstructured":"Bassett CAL, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD. Diphosphonates in the treatment of Myositis ossificans. Lancet. 1969;294(7625):845. https:\/\/doi.org\/10.1016\/S0140-6736(69)92293-4.","journal-title":"Lancet"},{"issue":"7706","key":"1251_CR35","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(71)91447-4","volume":"297","author":"R Smith","year":"1971","unstructured":"Smith R, Russell RGG, Margaret Bishop M. Diphosphonates and Paget\u2019s disease of bone. Lancet. 1971;297(7706):945\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(71)91447-4.","journal-title":"Lancet"},{"key":"1251_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00003086-197107000-00022","volume":"78","author":"WR Michael","year":"1971","unstructured":"Michael WR, Kino WR, Francis MD. Effectiveness of diphosphonates in preventing osteoporosis of disuse in the rat. Clin Orthop Relat Res. 1971;78:271\u20136. https:\/\/doi.org\/10.1097\/00003086-197107000-00022.","journal-title":"Clin Orthop Relat Res"},{"issue":"11","key":"1251_CR37","first-page":"986","volume":"16","author":"AJ Tofe","year":"1975","unstructured":"Tofe AJ, Francis MD, Harvey WJ. Correlation of neoplasms with incidence and localization of skeletal metastases: an analysis of 1,355 diphosphonate bone scans. J Nucl Med. 1975;16(11):986\u20139.","journal-title":"J Nucl Med"},{"issue":"4","key":"1251_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0190-9622(86)70228-4","volume":"15","author":"G St\u00fcttgen","year":"1986","unstructured":"St\u00fcttgen G. Historical perspectives of tretinoin. J Am Acad Dermatol. 1986;15(4):735\u201340. https:\/\/doi.org\/10.1016\/S0190-9622(86)70228-4.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1251_CR39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood.V72.2.567.567","volume":"72","author":"M Huang","year":"1988","unstructured":"Huang M, Ye Y, Chen S, Chai J, Lu J, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567\u201372. https:\/\/doi.org\/10.1182\/blood.V72.2.567.567.","journal-title":"Blood"},{"issue":"11","key":"1251_CR40","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1111\/j.1349-7006.2011.02045.x","volume":"102","author":"T Kamimura","year":"2011","unstructured":"Kamimura T, Miyamoto T, Harada M, Akashi K. Advances in therapies for acute promyelocytic leukemia. Cancer Sci. 2011;102(11):1929\u201337. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.02045.x.","journal-title":"Cancer Sci"},{"key":"1251_CR41","unstructured":"Roche. Vesanoid\u00ae (tretinoin) capsules. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020438s006lbl.pdf. Accessed Oct 2022."},{"issue":"2","key":"1251_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00897020539a","volume":"7","author":"R Bentley","year":"2002","unstructured":"Bentley R, Chasteen TG. Arsenic curiosa and humanity. Chem Educ. 2002;7(2):51\u201360. https:\/\/doi.org\/10.1007\/s00897020539a.","journal-title":"Chem Educ"},{"issue":"S2","key":"1251_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.6-suppl_2-1","volume":"6","author":"KH Antman","year":"2001","unstructured":"Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist. 2001;6(S2):1\u20132. https:\/\/doi.org\/10.1634\/theoncologist.6-suppl_2-1.","journal-title":"Oncologist"},{"issue":"9","key":"1251_CR44","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","volume":"89","author":"Z-X Shen","year":"1997","unstructured":"Shen Z-X, Chen G-Q, Ni J-H, Li X-S, Xiong S-M, Qiu Q-Y, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354\u201360. https:\/\/doi.org\/10.1182\/blood.V89.9.3354.","journal-title":"Blood"},{"issue":"10","key":"1251_CR45","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1182\/blood.V94.10.3315.422k16_3315_3324","volume":"94","author":"C Niu","year":"1999","unstructured":"Niu C, Yan H, Yu T, Sun H-P, Liu J-X, Li X-S, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94(10):3315\u201324. https:\/\/doi.org\/10.1182\/blood.V94.10.3315.422k16_3315_3324.","journal-title":"Blood"},{"issue":"18","key":"1251_CR46","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","volume":"19","author":"SL Soignet","year":"2001","unstructured":"Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19(18):3852\u201360. https:\/\/doi.org\/10.1200\/JCO.2001.19.18.3852.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1251_CR47","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.6004\/jnccn.2013.0127","volume":"11","author":"MR O\u2019Donnell","year":"2013","unstructured":"O\u2019Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia, version 2.2013. J Natl Compr Cancer Netw. 2013;11(9):1047\u201355. https:\/\/doi.org\/10.6004\/jnccn.2013.0127.","journal-title":"J Natl Compr Cancer Netw."},{"key":"1251_CR48","unstructured":"Centers for Disease Control and Prevention. BCG vaccine fact sheet. https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/prevention\/bcg.htm. Accessed Dec 2022"},{"key":"1251_CR49","doi-asserted-by":"publisher","unstructured":"Math\u00e9 G, Amiel JL, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, De Vassal F. Active immunotherapy for acute lymphoblastic leukaemia. Lancet. 1969;1(7597):697-9. https:\/\/doi.org\/10.1016\/s0140-6736(69)92648-8.","DOI":"10.1016\/s0140-6736(69)92648-8"},{"key":"1251_CR50","doi-asserted-by":"publisher","unstructured":"Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ, Sparks FC. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg. 1974;180(4):635-43. https:\/\/doi.org\/10.1097\/00000658-197410000-00029.","DOI":"10.1097\/00000658-197410000-00029"},{"key":"1251_CR51","unstructured":"Coe JE, Feldman JD. Extracutaneous delayed hypersensitivity, particularly in the guinea-pig bladder. Immunology. 1966;10(2):127-36."},{"key":"1251_CR52","unstructured":"Bloomberg SD, Brosman SA, Hausman MS, Cohen A, Battenberg JD. The effects of BCG on the dog bladder. Invest Urol. 1975;12(6):423-7."},{"issue":"2","key":"1251_CR53","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette\u2013Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180\u20132. https:\/\/doi.org\/10.1016\/S0022-5347(17)58737-6.","journal-title":"J Urol"},{"issue":"1","key":"1251_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.juro.2007.08.122","volume":"179","author":"HW Herr","year":"2008","unstructured":"Herr HW, Morales A. History of Bacillus Calmette\u2013Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008;179(1):53\u20136. https:\/\/doi.org\/10.1016\/j.juro.2007.08.122.","journal-title":"J Urol"},{"key":"1251_CR55","unstructured":"National Library of Medicine, DailyMed. Thalomid-thalidomide capsule. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=2eda833b-1357-4ed4-a093-194524fcb061. Accessed Dec 2022"},{"issue":"3","key":"1251_CR56","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/cpt196563292","volume":"6","author":"KB Olson","year":"1965","unstructured":"Olson KB, Hall TC, Horton J, Khung CL. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol Ther. 1965;6(3):292\u20137. https:\/\/doi.org\/10.1002\/cpt196563292.","journal-title":"Clin Pharmacol Ther"},{"issue":"21","key":"1251_CR57","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565\u201371. https:\/\/doi.org\/10.1056\/NEJM199911183412102.","journal-title":"N Engl J Med"},{"issue":"13","key":"1251_CR58","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","volume":"26","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar SV, Rosi\u00f1ol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26(13):2171\u20137. https:\/\/doi.org\/10.1200\/JCO.2007.14.1853.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1251_CR59","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1152\/ajplegacy.1948.153.3.586","volume":"153","author":"RP Ahlquist","year":"1948","unstructured":"Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol Content. 1948;153(3):586\u2013600. https:\/\/doi.org\/10.1152\/ajplegacy.1948.153.3.586.","journal-title":"Am J Physiol Content"},{"issue":"4","key":"1251_CR60","first-page":"336","volume":"24","author":"MP Stapleton","year":"1997","unstructured":"Stapleton MP. Sir James black and propranolol. The role of the basic sciences in the history of cardiovascular pharmacology. Tex Hear Inst J. 1997;24(4):336\u201342.","journal-title":"Tex Hear Inst J"},{"issue":"3","key":"1251_CR61","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/21548331.2022.2040920","volume":"50","author":"SG Chrysant","year":"2022","unstructured":"Chrysant SG, Chrysant GS. Antihypertensive and cardioprotective effects of three generations of beta-adrenergic blockers: an historical perspective. Hosp Pract. 2022;50(3):196\u2013202. https:\/\/doi.org\/10.1080\/21548331.2022.2040920.","journal-title":"Hosp Pract"},{"issue":"8","key":"1251_CR62","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1404710.","journal-title":"N Engl J Med"},{"key":"1251_CR63","unstructured":"Annex I: Hemangiol: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hemangiol-epar-product-information_en.pdf. Accessed Dec 2022"},{"issue":"4","key":"1251_CR64","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1111\/bcp.14593","volume":"87","author":"F Socchi","year":"2021","unstructured":"Socchi F, Bigorre M, Normandin M, Captier G, Bessis D, Mondain M, et al. Hemangiol in infantile haemangioma: a paediatric post-marketing surveillance drug study. Br J Clin Pharmacol. 2021;87(4):1970\u201380. https:\/\/doi.org\/10.1111\/bcp.14593.","journal-title":"Br J Clin Pharmacol"},{"key":"1251_CR65","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20\u201333. https:\/\/doi.org\/10.1016\/j.jhealeco.2016.01.012.","journal-title":"J Health Econ"},{"key":"1251_CR66","first-page":"9","volume":"12","author":"A Persidis","year":"2011","unstructured":"Persidis A. The benefits of drug repositioning. Drug Discov World. 2011;12:9\u201312.","journal-title":"Drug Discov World."},{"key":"1251_CR67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve RD productivity: the pharmaceutical industry\u2019s grand challenge. Nat Rev Drug Discov. 2010;9:203\u201314. https:\/\/doi.org\/10.1038\/nrd3078.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1251_CR68","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/proteomes4030028","volume":"4","author":"H Matthews","year":"2016","unstructured":"Matthews H, Hanison J, Nirmalan N. \u201cOmics\u201d-informed drug and biomarker discovery: opportunities, challenges and future perspectives. Proteomes. 2016;4(3):28. https:\/\/doi.org\/10.3390\/proteomes4030028.","journal-title":"Proteomes"},{"issue":"1","key":"1251_CR69","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40\u201351. https:\/\/doi.org\/10.1038\/nbt.2786.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"1251_CR70","doi-asserted-by":"publisher","first-page":"e1008060","DOI":"10.1371\/journal.pgen.1008060","volume":"15","author":"G Gibson","year":"2019","unstructured":"Gibson G. On the utilization of polygenic risk scores for therapeutic targeting. PLOS Genet. 2019;15(4):e1008060. https:\/\/doi.org\/10.1371\/journal.pgen.1008060.","journal-title":"PLOS Genet"},{"issue":"1","key":"1251_CR71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cels.2017.01.005","volume":"4","author":"NS Baliga","year":"2017","unstructured":"Baliga NS, Bj\u00f6rkegren JLM, Boeke JD, Boutros M, Crawford NPS, Dudley AM, et al. The state of systems genetics in 2017. Cell Syst. 2017;4(1):7\u201315. https:\/\/doi.org\/10.1016\/j.cels.2017.01.005.","journal-title":"Cell Syst"},{"issue":"8","key":"1251_CR72","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrg3934","volume":"16","author":"NN Parikshak","year":"2015","unstructured":"Parikshak NN, Gandal MJ, Geschwind DH. Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders. Nat Rev Genet. 2015;16(8):441\u201358. https:\/\/doi.org\/10.1038\/nrg3934.","journal-title":"Nat Rev Genet"},{"issue":"6","key":"1251_CR73","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrd4309","volume":"13","author":"D Cook","year":"2014","unstructured":"Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca\u2019s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419\u201331. https:\/\/doi.org\/10.1038\/nrd4309.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"1251_CR74","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.5980\/jpnjurol1928.77.11_1784","volume":"77","author":"K Mori","year":"1986","unstructured":"Mori K, Lamm DL, Crawford ED. A comparative clinical trial of intravesical BCG and adriamycin treatment in superficial bladder cancer. Jpn J Urol. 1986;77(11):1784\u20139. https:\/\/doi.org\/10.5980\/jpnjurol1928.77.11_1784.","journal-title":"Jpn J Urol"},{"issue":"1","key":"1251_CR75","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","volume":"124","author":"DL Lamm","year":"1980","unstructured":"Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette\u2013Guerin immunotherapy of superficial bladder cancer. J Urol. 1980;124(1):38\u201342. https:\/\/doi.org\/10.1016\/S0022-5347(17)55282-9.","journal-title":"J Urol"},{"issue":"3","key":"1251_CR76","first-page":"359","volume":"21","author":"FJ Camacho","year":"1980","unstructured":"Camacho FJ, Pinsky CM, Herr HW, Whitmore WF, Oettgen H. Treatment of superficial bladder cancer with intravesical BCG. Proc Am Soc Clin Oncol. 1980;21(3):359\u201363.","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"24","key":"1251_CR77","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, de la Roque ED, Hubiche T, Boralevi F, Thambo J-B, Ta\u00efeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649\u201351. https:\/\/doi.org\/10.1056\/NEJMc0708819.","journal-title":"N Engl J Med"},{"issue":"2","key":"1251_CR78","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1542\/peds.2010-0029","volume":"128","author":"M Hogeling","year":"2011","unstructured":"Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128(2):e259\u201366. https:\/\/doi.org\/10.1542\/peds.2010-0029.","journal-title":"Pediatrics"},{"key":"1251_CR79","doi-asserted-by":"publisher","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, DumasdelaRoque E, Nacka F, Abouelfath A, Grenier N, Rebola M, et al. Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age. Br J Dermatol. 2013;169(1):181\u20133. https:\/\/doi.org\/10.1111\/bjd.12217. Accessed Dec 2022.","DOI":"10.1111\/bjd.12217"},{"key":"1251_CR80","unstructured":"How much does an oncology clinical trial cost. https:\/\/www.linkedin.com\/pulse\/how-much-does-oncology-clinical-trial-cost-patricio-ledesma\/. Accessed Dec 2022."},{"key":"1251_CR81","doi-asserted-by":"publisher","unstructured":"Williams SB, Howard LE, Foster ML, Klaassen Z, Sieluk J, De Hoedt, et al. Estimated costs and long-term outcomes of patients with high-risk non\u2013muscle-invasive bladder cancer treated with Bacillus Calmette\u2013Gu\u00e9rin in the veterans affairs health system. JAMA Netw Open 2021;4(3):e213800. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3800.","DOI":"10.1001\/jamanetworkopen.2021.3800"},{"issue":"50","key":"1251_CR82","doi-asserted-by":"publisher","first-page":"7308","DOI":"10.1016\/j.vaccine.2021.08.026","volume":"39","author":"DL Lamm","year":"2021","unstructured":"Lamm DL, Morales A. A BCG success story: from prevention of tuberculosis to optimal bladder cancer treatment. Vaccine. 2021;39(50):7308\u201318. https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.026.","journal-title":"Vaccine"},{"key":"1251_CR83","doi-asserted-by":"crossref","unstructured":"Maureen R.A. Thalidomide purpose immunomodulator. Chemical and engineering news. American Chemical Society. Pharmaceuticals. 2005;83(25). http:\/\/cen.acs.org\/articles\/83\/i25\/Thalidomide.html.\nAccessed Dec 2022.","DOI":"10.1021\/cen-v083n025.p122"},{"issue":"7","key":"1251_CR84","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1001\/jamaoncol.2016.0648","volume":"2","author":"SB Dusetzina","year":"2016","unstructured":"Dusetzina SB. Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000\u20132014. JAMA Oncol. 2016;2(7):960. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0648.","journal-title":"JAMA Oncol"},{"key":"1251_CR85","unstructured":"Thalomid prices, coupons and patient assistance programs. https:\/\/www.drugs.com\/price-guide\/thalomid. Accessed Dec 2022."},{"key":"1251_CR86","unstructured":"Hemangeol prices\u2014(propranolol hcl). https:\/\/www.pharmacychecker.com\/hemangeol\/?src=drug-suggest#us-prices. Accessed Dec 2022."},{"key":"1251_CR87","unstructured":"Propranolol hydrochloride (hemangiol) [Internet]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK476403\/table\/app7.t1\/. Accessed Dec 2022."},{"key":"1251_CR88","doi-asserted-by":"publisher","first-page":"004695802110248","DOI":"10.1177\/00469580211024894","volume":"58","author":"M Chaikumbung","year":"2021","unstructured":"Chaikumbung M. Democracy, culture and cancer patients\u2019 willingness to pay for healthcare services: a meta-analysis. Inq J Health Care Organ Provision, Financ. 2021;58:004695802110248. https:\/\/doi.org\/10.1177\/00469580211024894.","journal-title":"Inq J Health Care Organ Provision, Financ"},{"issue":"6","key":"1251_CR89","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.mayocp.2016.04.028","volume":"91","author":"V Prasad","year":"2016","unstructured":"Prasad V, Mailankody S. The UK cancer drugs fund experiment and the US cancer drug cost problem. Mayo Clin Proc. 2016;91(6):707\u201312. https:\/\/doi.org\/10.1016\/j.mayocp.2016.04.028.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"1251_CR90","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/S1470-2045(17)30322-4","volume":"18","author":"TK Burki","year":"2017","unstructured":"Burki TK. Cancer drugs fund of minimal benefit. Lancet Oncol. 2017;18(6):e305. https:\/\/doi.org\/10.1016\/S1470-2045(17)30322-4.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1251_CR91","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrclinonc.2016.12","volume":"13","author":"R Sullivan","year":"2016","unstructured":"Sullivan R, Aggarwal A. Putting a price on cancer. Nat Rev Clin Oncol. 2016;13(3):137\u20138. https:\/\/doi.org\/10.1038\/nrclinonc.2016.12.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1251_CR92","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.mayocp.2012.07.007","volume":"87","author":"M Siddiqui","year":"2012","unstructured":"Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012;87(10):935\u201343. https:\/\/doi.org\/10.1016\/j.mayocp.2012.07.007.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"1251_CR93","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1200\/JOP.2016.014431","volume":"13","author":"P Savage","year":"2017","unstructured":"Savage P, Mahmoud S, Patel Y, Kantarjian H. Cancer drugs: an international comparison of postlicensing price inflation. J Oncol Pract. 2017;13(6):e538\u201342. https:\/\/doi.org\/10.1200\/JOP.2016.014431.","journal-title":"J Oncol Pract"},{"key":"1251_CR94","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2018.886","author":"P Pantziarka","year":"2018","unstructured":"Pantziarka P, Verbaanderd C, Sukhatme V, Capistrano R, Crispino S, Gyawali B, et al. ReDO_DB: the repurposing drugs in oncology database. Ecancermedicalscience. 2018. https:\/\/doi.org\/10.3332\/ecancer.2018.886.","journal-title":"Ecancermedicalscience."},{"key":"1251_CR95","unstructured":"Dollars for Docs: how industry dollars reached your doctors. https:\/\/projects.propublica.org\/docdollars\/. Accessed Dec 2022."},{"issue":"4","key":"1251_CR96","doi-asserted-by":"publisher","first-page":"e0152402","DOI":"10.1371\/journal.pone.0152402","volume":"11","author":"PC Elwood","year":"2016","unstructured":"Elwood PC, Morgan G, Pickering JE, Galante J, Weightman AL, Morris D, et al. Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies. PLoS ONE. 2016;11(4):e0152402. https:\/\/doi.org\/10.1371\/journal.pone.0152402.","journal-title":"PLoS ONE"},{"issue":"6","key":"1251_CR97","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/annonc\/mds113","volume":"23","author":"C Bosetti","year":"2012","unstructured":"Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23(6):1403\u201315. https:\/\/doi.org\/10.1093\/annonc\/mds113.","journal-title":"Ann Oncol"},{"key":"1251_CR98","unstructured":"National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed Dec 2022."},{"issue":"11","key":"1251_CR99","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","volume":"126","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, et al. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood. 2015;126(11):1294\u2013301. https:\/\/doi.org\/10.1182\/blood-2014-12-613927. Accessed Dec 2022.","journal-title":"Blood"},{"issue":"9","key":"1251_CR100","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","volume":"127","author":"S Zweegman","year":"2016","unstructured":"Zweegman S, van der Holt B, Mellqvist U-H, Salomo M, Bos GMJ, Levin M-D, et al. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. 2016;127(9):1109\u201316. https:\/\/doi.org\/10.1182\/blood-2015-11-679415.","journal-title":"Blood"},{"issue":"4","key":"1251_CR101","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1590\/0102-311XPE010414","volume":"30","author":"FJR Paumgartten","year":"2014","unstructured":"Paumgartten FJR. Thalidomide and its analogues: comparative clinical efficacy and safety, and cost-effectiveness. Cad Saude Publ. 2014;30(4):684\u20136. https:\/\/doi.org\/10.1590\/0102-311XPE010414.","journal-title":"Cad Saude Publ"},{"issue":"10","key":"1251_CR102","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","volume":"18","author":"M Mohty","year":"2018","unstructured":"Mohty M, Terpos E, Mateos M-V, Cavo M, Lejniece S, Beksac M, EMMOS Investigators, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk. 2018;18(10):e401\u201319. https:\/\/doi.org\/10.1016\/j.clml.2018.06.018. Accessed Dec 2022.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1251_CR103","unstructured":"Walker N. Accelerating drug development through repurposing, repurposing and rescue. Pharmaceutical OutsourcingTM. 2017. http:\/\/www.pharmoutsourcing.com\/Featured-Articles\/345076-Accelerating-Drug-Development-Through-Repurposing-Repositioning-and-Rescue\/."},{"issue":"10059","key":"1251_CR104","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/S0140-6736(16)32184-5","volume":"388","author":"J Clark","year":"2016","unstructured":"Clark J, McGoey L. The black box warning on philanthrocapitalism. Lancet. 2016;388(10059):2457\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(16)32184-5.","journal-title":"Lancet"},{"issue":"1","key":"1251_CR105","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/challe10010024","volume":"10","author":"C Butler","year":"2019","unstructured":"Butler C. Philanthrocapitalism: promoting global health but failing planetary health. Challenges. 2019;10(1):24. https:\/\/doi.org\/10.3390\/challe10010024.","journal-title":"Challenges"},{"issue":"2","key":"1251_CR106","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.mayocpiqo.2020.09.016","volume":"5","author":"S Tabatabavakili","year":"2021","unstructured":"Tabatabavakili S, Khan R, Scaffidi MA, Gimpaya N, Lightfoot D, Grover SC. Financial conflicts of interest in clinical practice guidelines: a systematic review. Mayo Clin Proc Innov Qual Outcomes. 2021;5(2):466\u201375. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2020.09.016.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01251-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01251-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01251-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T15:26:02Z","timestamp":1681313162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01251-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":106,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1251"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01251-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"14 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aurora Gonzalez-Fierro, Adriana Romo-P\u00e9rez, Alma Ch\u00e1vez-Blanco, Guadalupe Dominguez-Gomez, and Alfonso Duenas-Gonzalez declare they have no conflicts of interest in relation to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"No fudning was used to prepare this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no data associated with this manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were contributed to the conception, planning, writing of the review and approved the final draft.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}